Skip to main content
European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-06-18

Model-based preclinical development of anti-tuberculosis drug combinations

Cel

Drug development in TB requires new integrated methods to transition the novel combination regimens needed to shorten first-line therapy and combat multi-drug resistance. Although new agents are emerging, the path to registration of such regimens remains uncertain while capacity for pivotal trials is limited. Selection and optimization of drug combinations for development depends on preclinical systems which do not capture in vivo pharmacodynamics of heterogeneous states of M.tuberculosis.These systems are diverse and their predictive power for clinical trial outcomes is uncertain, escalating risks during development. To overcome these bottlenecks, PreDiCT-TB will take a comprehensive model based approach, synthesizing and integrating preclinical and clinical information. We will harness innovative technologies to develop an integrated set of predictive pre-clinical tools to facilitate selection of the best drug combinations and dosages for entry into optimized clinical studies. We will develop diverse existing and innovative experimental models of pharmacodynamics from extracellular MTB organisms, through to acute and chronic animal models in different species. We will enhance these systems using innovative single cell and functional imaging, novel mycobacteriological approaches and identification of biomarkers of lethality and sterilization. We will represent these critical data using multi-scale mathematical approaches incorporating PK-PD and disease models, supported by a translational data integration platform.The aim is an optimized decision pathway for combination regimens to progress to innovative early clinical trials. We will develop this modelling framework using a training set of reference compounds and subsequently update it with emerging data from new compounds. We believe that this comprehensive approach is the only way to overcome existing gaps in translation and create an effective and rapid drug development strategy for European researchers.

Dziedzina nauki

Program(-y)

Temat(-y)

Zaproszenie do składania wniosków

IMI-JU-03-2010
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)

Koordynator

GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL
Wkład UE
Brak danych
Adres
C/ SEVERO OCHOA NUMERO 2 PARQUE TECNOLOGICO DE MAD
28760 TRES CANTOS MADRID
Hiszpania

Zobacz na mapie
Region
Comunidad de Madrid Comunidad de Madrid Madrid
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt administracyjny
Sally Miles (-)
Kierownik naukowy
Justin Green (Dr)
Linki
Koszt całkowity
Brak danych

Uczestnicy (19)

Udostępnij tę stronę

Pobierz

Ostatnia aktualizacja: 10 Lutego 2022

Moja broszura

Permalink: https://cordis.europa.eu/project/id/115337/pl

European Union, 2024